CLRN2

Across TCGA pan-cancer cohorts, CLRN2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CLRN2 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CLRN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLRN2 expression acts as an unfavorable survival marker.

COAD and PRAD are the cancer types where CLRN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.414	0.812	<.001	19	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CLRN2–COAD (OS)

Open the COAD breakdown →